BioRisk Association of the Philippines 2015, Inc. (BRAP2015)

We are inviting everyone to the BRAP–PAMET International Webinar on Essential Biosafety for COVID-19. This event is granted with 2 CPD units. You need a Zoom account to register. Go to this link to register: http://tiny.cc/brappametwebinar

Many in-house and commercial assays that detect the COVID-19 virus have been developed or are currently under development. Many of these molecular assays are currently being validated in partner laboratories. An overview of assays that have applied to FIND for participation in their assay assessment work can be found here.

In-house developed molecular assays

At the beginning of the outbreak, WHO supported access to COVID-19 in-house PCR protocols assays by posting them online on the WHO website. Protocols that have been shared can be accessed here. Being listed in this document does not imply any endorsement or validation by WHO. These protocol postings online are not being updated and may not reflect subsequent refinements of the assays.

Lifted from WHO publications page

WHO has established a shipment mechanism to expedite and cover the costs of the shipment of clinical samples from patients with suspected COVID-19 from the country of collection to one of the WHO reference laboratories providing confirmatory molecular testing for COVID-19. This document explains the process and documentation required for shipment of specimens.

 Access the document here. (updated 31 March 2020)

Lifted from the WHO publications page.